In a coup for Chemocentryx Inc., Switzerland's Vifor Pharma Ltd. has agreed to pay $85 million in cash and equity to license commercial rights to CCX168, the company's complement 5a receptor inhibitor for orphan and rare renal diseases. The deal, which covers multiple ex-U.S. markets, is part of a transformational year, Chemocentryx CEO and President Tom Schall told BioWorld Today.